CEQ 508

Drug Profile

CEQ 508

Alternative Names: CEQ508

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Marina Biotech
  • Class Antineoplastics; RNA
  • Mechanism of Action Beta catenin inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Familial adenomatous polyposis

Most Recent Events

  • 10 Jul 2017 The primary endpoint was met in the phase I/II START-FAP trial in Familial adenomatous polyposis
  • 13 Mar 2017 Marina Biotech completes phase I part of the START-FAP phase I/II trial in Familial adenomatous polyposis in USA
  • 18 Sep 2015 Clinical development is ongoing the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top